Direct and indirect photodynamic therapy effects on the cellular and molecular components of the tumor microenvironment

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1835, Issue 1, 2013, Pages 36-45

  Milla Sanabria, Laura ^a   Rodríguez, Matías Exequiel ^a   Cogno, Ingrid Sol ^a   Rumie Vittar, Natalia Belén ^a   Pansa, María Florencia ^a   Lamberti, María Julia ^a   Rivarola, Viviana Alicia ^a  

^a DEPARTAMENTO DE QUÍMICA   (Argentina)

Author keywords

Autophagy; Cancer; Cell adhesion; Extracellular matrix; Immune system; Photodynamic therapy

Indexed keywords

ANGIOPOIETIN; CADHERIN; FIBROBLAST GROWTH FACTOR; GELATINASE A; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; SELECTIN; STROMELYSIN; TRANSFORMING GROWTH FACTOR BETA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ANGIOGENESIS; AUTOPHAGY; CANCER RESISTANCE; CANCER THERAPY; CELL ADHESION; CELL DEATH; CELL KILLING; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DIRECT PHOTODYNAMIC THERAPY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HYPOXEMIA; IMMUNE SYSTEM; INDIRECT PHOTODYNAMIC THERAPY; MOLECULAR MECHANICS; NONHUMAN; OXIDATIVE STRESS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; TUMOR CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ANIMALS; AUTOPHAGY; EXTRACELLULAR MATRIX; HUMANS; NEOPLASMS; PHOTOCHEMOTHERAPY; TUMOR MICROENVIRONMENT;

EID: 84868588163     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2012.10.001     Document Type: Review

References (129)

1. Brown S.B., Brown E.A., Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol. 2004, 5:497-508.
2. Dougherty T.J. An update on photodynamic therapy applications. J. Clin. Laser Med. Surg. 2002, 20:3-7.
3. Macdonald I.J., Dougherty T.J. Basic principles of photodynamic therapy. J. Porphyrins Phthalocyanines 2001, 5:105-129.
4. Castano A.P., Demidova T.N., Hamblin M.R. Mechanisms in photodynamic therapy: part two-cellular signaling, cell metabolism and modes of cell death. Photodiagnosis Photodyn. Ther. 2005, 2:1-23.
5. Brancaleon L. Laser and nonlaser light sources for photodynamic therapy. Lasers Med. Sci. 2002, 17:173-186.
6. Pinton C. Repetitive photodynamic therapy with topical delta-aminolaevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumors. J. Photochem. Photobiol. 1995, 29:53-57.
7. Hirschberg Henry, Sørensen Dag R., Angell-Petersen Even, Peng Qian, Tromberg Bruce, Sun Chung-Ho, Spetalen Signe Repetitive photodynamic therapy of malignant brain tumors. J. Environ. Pathol. Toxicol. Oncol. 2006, 25:261-279.
8. Madsen S.J., Sun C., Tromberg B.J., Hirschberg H. Repetitive 5-aminolevulinic acid-mediated photodynamic therapy on human glioma spheroids. J. Neurooncol 2003, 62:243-250.
9. Trédan O., Galmarini C.M., Patel K., Tannock I.F. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 2007, 99:1441-1454.
10. Peng Q., Nesland J.M. Effects of photodynamic therapy on tumor stroma. Ultrastruct. Pathol. 2004, 28:333-340.
11. Kousis P.C., Henderson B.W., Maier P.G., Gollnick S.O. Photodynamic therapy enhancement of antitumor immunity is regulated by neutrophils. Cancer Res. 2007, 67:10501-10510.
12. Gollnick S.O. Stimulation of the host immune response by photodynamic therapy (PDT). Proceedings of SPIE 2004, 60-70. SPIE.
13. Gollnick S.O., Evans S.S., Baumann H., Owczarczak B., Maier P., Vaughan L., et al. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br. J. Cancer 2003, 1:1772-1779.
14. Nowis D., Makowski M., Stokłosa T., Legat M., Issat T., Gołab J. Direct tumor damage mechanisms of photodynamic therapy. Rev. Lit. Arts Am. 2005, 52:339-352.
15. Mroz P., Yaroslavsky A., Kharkwal G.B., Hamblin M.R. Cell death pathways in photodynamic therapy of cancer. Cancers 2011, 3:2516-2539.
16. Casas A., Di Venosa G., Hasan T., Batlle Al Mechanisms of resistance to photodynamic therapy. Curr. Med. Chem. 2011, 18:2486-2515.
17. Kim S.H., Turnbull J., Guimond S. Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J. Endocrinol. 2011, 209:139-151.
18. Ungefroren H., Sebens S., Seidl D., Lehnert H., Hass R. Interaction of tumor cells with the microenvironment. CCS 2011, 9:18.
19. Lu P., Weaver V.M., Werb Z. The extracellular matrix: a dynamic niche in cancer progression. JCB 2012, 196:395-406.
20. Velling T., Nilsson S., Stefansson A., Johansson S. Beta1-Integrins induce phosphorylation of Akt on serine 473 independently of focal adhesion kinase and Src family kinases. EMBO Rep. 2004, 5:901-905.
21. Estrugo D., Fischer A., Hess F., Scherthan H., Belka C., Cordes N. Ligand bound beta1 integrins inhibit procaspase-8 for mediating cell adhesion-mediated drug and radiation resistance in human leukemia cells. PLoS One 2007, 2:e269.
22. Zarbock A., Kempf T., Wollert K.C., Vestweber D. Leukocyte integrin activation and deactivation: novel mechanisms of balancing inflammation. J. Mol. Med. 2012, 90:353-359.
23. Dowlati A., Gray R., Sandler A.B., Schiller J.H., Johnson D.H. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study. Clin. Cancer Res. 2008, 14:1407-1412.
24. Gassmann P., Kang M.-L., Mees S.T., Haier J. In vivo tumor cell adhesion in the pulmonary microvasculature is exclusively mediated by tumor cell-endothelial cell interaction. BMC Cancer 2010, 10:177.
25. Mohamet L., Hawkins K., Ward C.M. Loss of function of e-cadherin in embryonic stem cells and the relevance to models of tumorigenesis. J. Oncol. 2011, 2011:352616.
26. Baranwal S., Alahari S.K. Molecular mechanisms controlling E-cadherin expression in breast cancer. Biochem. Biophys. Res. Commun. 2009, 384:6-11.
27. Nader H.B., Medicina E.P.D. Effect of photodynamic therapy on the extracellular matrix and associated components. Braz. J. Med. Biol. Res. 2007, 40.
28. Verrico A.K., Moore J.V. Expression of the collagen. Related heat shock protein HSP47 in fibroblasts treated with hyperthermia or photodynamic therapy. Br. J. Cancer 1997, 76:719-724.
29. Verrico A.K., Haylett A.K., Moore J.V. In vivo expression of the collagen-related heat shock protein HSP47, following hyperthermia or photodynamic therapy. Lasers Med. Sci. 2001, 16:192-198.
30. Nelson J.S., Liaw L.H., Orenstein A., Roberts W.G., Berns M.W. Mechanism of tumor destruction following photodynamic therapy with hematoporphyrin derivative, chlorin, and phthalocyanine. J. Natl. Cancer Inst. 1988, 80:1599-1605.
31. Maas A.L., Carter S.L., Wileyto E.P. Tumor vascular microenvironment determines responsiveness to photodynamic therapy. Cancer Res. 2012, 72:2079-2088.
32. Statius van Eps R.G., Adili F., Watkins M.T., Anderson R.R., LaMuraglia G.M. Photodynamic therapy of extracellular matrix stimulates endothelial cell growth by inactivation of matrix-associated transforming growth factor-beta. Lab. Invest. 1997, 76:257-266.
33. Relf M., LeJeune S., Scott P.A., Fox S., Smith K., Leek R., Moghaddam A., Whitehouse R., Bicknell R. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary brea. Cancer Res. 1997, 57:963-969.
34. Carvalho P., Duarte C.B., Almeida R.D., Manadas B.J. Intracellular signaling mechanisms in photodynamic therapy. Rev. Lit. Arts Am. 2004, 1704:59-86.
35. Koukourakis M.I., Giatromanolaki A., Skarlatos J., Corti L., Blandamura S., Piazza M., et al. Hypoxia Inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer 2001, 1830-1832.
36. Ferrario A., von Tiehl K.F., Rucker N., Schwarz M.A., Gill P.S. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res. 2000, 60:4066-4069.
37. Shen H.R., Spikes J.D., Kopecekova P. Photodynamic crosslinking of proteins. I. Model studies using histidine- and lysinecontaining N-(2-hydroxypropyl) methacrylamide copolymers. J. Photochem. Photobiol. B 1996, 34:203-210.
38. Waterman P.R., Overhaus M., Heckenkamp J., Nigri G.R., Fungaloi P.F.C., Landis M.E., et al. Mechanisms of reduced human vascular cell migration after photodynamic therapy. Photochem. Photobiol. 2002, 75:46-50.
39. Overhaus M., Heckenkamp J., Kossodo S., Leszczynski D., LaMuraglia G.M. Photodynamic therapy generates a matrix barrier to invasive vascular cell migration. Circ. Res. 2000, 86:334-340.
40. Margaron P., Sorrenti R., Levy J.G. Photodynamic therapy inhibits cell adhesion without altering integrin expression. BBA - Mol. Cell. Res. 1997, 1359:200-210.
41. Runnels J.M., Chen N., Ortel B., Kato D., Hasan T. BPD-MA-mediated photosensitization in vitro and in vivo: cellular adhesion and beta1 integrin expression in ovarian cancer cells. Br. J. Cancer 1999, 80:946-953.
42. Uzdensky A.B., Juzeniene A., Kolpakova E., Hjortland G.O., Juzenas P. Photosensitization with protoporphyrin IX inhibits attachment of cancer cells to a substratum. Biochem. Biophys. Res. Commun. 2004, 322:452-457.
43. Galaz S., Espada J., Stockert J.C., Pacheco M., Sanz-Rodríguez F., Arranz R., Rello S., Cañete M., Villanueva Á., Esteller M. Loss of E-cadherin mediated cell-cell adhesion as an early trigger of apoptosis induced by photodynamic treatment. J. Cell. Physiol. 2002, 205:86-96.
44. Mayhew S., Vernon D., Schofield J., Griffiths J. Investigation of cross-resistance to a range of photosensitizers, hyperthermia and UV light in two radiation-induced fibrosarcoma cell strains resistant to photodynamic therapy in vitro. Photochem. Photobiol. 2001, 73:39-46.
45. Singh G., Wilson B., Sharkey S., Browman G. Resistance to photodynamic therapy in radiation induced fibrosarcoma-1 and chinese hamster ovary-multi-drug resistant cells in vitro. Photochem. Photobiol. 1991, 54:307-312.
46. Casas A., Perotti C., Ortel B., Di Venosa G., Saccoliti M., Batlle A. Tumor cell lines resistant to ALA-mediated photodynamic therapy and possible tools to target surviving cells. Int. J. Oncol. 2006, 9:397-405.
47. Milla L.N., Cogno I.S., Rodríguez M.E., Sanz-Rodríguez F., Zamarrón A., Gilaberte Y., et al. Isolation and characterization of squamous carcinoma cells resistant to photodynamic therapy. J. Cell. Biochem. 2011, 112:2266-2278.
48. Casas A., Di Venosa G., Vanzulli S., Perotti C., Mamome L., Rodriguez L., et al. Decreased metastatic phenotype in cells resistant to aminolevulinic acid-photodynamic therapy. Cancer Lett. 2008, 271:342-351.
49. Casas A., Sanz-Rodriguez F., Di Venosa G., Rodriguez L., Mamone L., Blázquez A., et al. Disorganisation of cytoskeleton in cells resistant to photodynamic treatment with decreased metastatic phenotype. Cancer Lett. 2008, 270:56-65.
50. Kopelman R., Lee Koo Y.-E., Philbert M., Moffat B.A., Ramachandra Reddy G., McConville P., et al. Multifunctional nanoparticle platforms for in vivo MRI enhancement and photodynamic therapy of a rat brain cancer. J. Magn. Magn. Mater. 2005, 293:404-410.
51. Rousset N., Vonarx V., Eléouet S., Carré J., Kerninon E., Lajat Y. Effects of photodynamic therapy on adhesion molecules and metastasis. J. Photochem. Photobiol. B 1999, 52:65-73.
52. Sluiter W., de Vree W.J., Pietersma A., Koster J.F. Prevention of late lumen loss after coronary angioplasty by photodynamic therapy: role of activated neutrophils. Mol. Cell. Biochem. 1996, 157:233-238.
53. de Vree W.J., Fontijne-Dorsman A.N., Koster J.F., Sluiter W. Photodynamic treatment of human endothelial cells promotes the adherence of neutrophils in vitro. Br. J. Cancer 1996, 73:1335-1340.
54. Volanti C., Gloire G., Vanderplasschen A., Jacobs N., Habraken Y., Piette J. Downregulation of ICAM-1 and VCAM-1 expression in endothelial cells treated by photodynamic therapy. Oncogene 2004, 23:8649-8658.
55. Bhuvaneswari R., Yuen Æ.Y. The effect of photodynamic therapy on tumor angiogenesis. Cell. Mol. Life Sci. 2009, 2275-2283.
56. Au S.T.C., Luk S., Jackson C., Ng H., Yow C. Differential effects of photofrin, 5-aminolevulinic acid and calphostin C on glioma cells. J. Photochem. Photobiol. B 2006, 85:92-101.
57. Lichtner N.R., Kaufmann A., Kittmann A., Rohdeschulz B., Walter J., Williams L., Ullrich A., Schirrmacher V. Ligand mediated activation of ectopic EGF receptor promotes matrix protein adhesion and lung colonization of rat mammary adenocarcinoma cells. Oncogene 1995, 10:1823-1832.
58. Azzam E.T.H. Collagen-induced activation of the Mr 72,000 type IV collagenase in normal and malignant human fibroblastoid cells. Cancer Res. 1992, 52:4540-4544.
59. Karrer S., Bosserhoff A.K., Weiderer P., Landthaler M., Szeimies R.-M. Influence of 5-aminolevulinic acid and red light on collagen metabolism of human dermal fibroblasts. J. Invest. Dermatol. 2003, 120:325-331.
60. Ferrario A., Chantrain C.F., von Tiehl K., Buckley S., Rucker N., Shalinsky D.R., et al. The matrix metalloproteinase inhibitor prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model. Cancer Res. 2004, 64:2328-2332.
61. Korbelik M. Induction of tumor immunity by photodynamic therapy. J. Clin. Laser Med. Surg. 1996, 14:329-334.
62. van Duijnhoven F.H., Aalbers R.I.J.M., Rovers J.P., Terpstra O.T., Kuppen P.J.K. The immunological consequences of photodynamic treatment of cancer, a literature review. Immunobiology 2003, 207:9.
63. Mroz P., Hashmi J.T., Huang Y.-Y., Lange N., Hamblin M.R. Stimulation of anti-tumor immunity by photodynamic therapy. Expert Rev. Clin. Immunol. 2011, 7:75-91.
64. Gollnick S.O., Brackett C.M. Enhancement of anti-tumor immunity by photodynamic therapy. Immunol. Res. 2010, 46:216-226.
65. Brackett C.M., Gollnick S.O. Photodynamic therapy enhancement of anti-tumor immunity. Photochem. Photobiol. Sci. 2011, 10:649-652.
66. Mroz P., Hamblin M.R. The immunosuppressive side of PDT. Photochem. Photobiol. Sci. 2011, 10:751-758.
67. Hunt D.W., Levy J.G. Immunomodulatory aspects of photodynamic therapy. Expert Opin. Investig. Drugs 1998, 7:57-64.
68. Frost G.A., Halliday G.M., Damian D.L. Photodynamic therapy-induced immunosuppression in humans is prevented by reducing the rate of light delivery. J. Invest. Dermatol. 2011, 131:962-968.
69. Canti G., Lattuada D., Nicolin A., Taroni P., Valentini G., Cubeddu R. Antitumor immunity induced by photodynamic therapy with aluminum disulfonated phthalocyanines and laser light. Anti-Cancer Drugs 1994, 5:443-447.
70. Korbelik M., Dougherty G.J. Photodynamic Therapy-mediated Immune Response against Subcutaneous Mouse Tumors Photodynamic Therapy-mediated Immune Response against Subcutaneous. Cancer Res. 1999, 1941-1946.
71. Granville D.J., McManus B.M., Hunt D.W. Photodynamic therapy: shedding light on the biochemical pathways regulating porphyrin-mediated cell death. Histol. Histopathol. 2001, 16:309-317.
72. Girotti A.W. Photosensitized oxidation of membrane lipids: reaction pathways, cytotoxic effects, and cytoprotective mechanisms. J. Photochem. Photobiol. B 2001, 63:103-113.
73. Krosl G., Korbelik M., Dougherty G.J. Induction of immune cell infiltration into murine SCCVII tumour by photofrin-based photodynamic therapy. Br. J. Cancer 1995, 71:549-555.
74. Cecic I., Stott B., Korbelik M. Acute phase response-associated systemic neutrophil mobilization in mice bearing tumors treated by photodynamic therapy. Int. Immunopharmacol. 2006, 6:1259-1266.
75. Korbelik M., Cecic I. Complement activation cascade and its regulation: relevance for the response of solid tumors to photodynamic therapy. J. Photochem. Photobiol. B 2008, 93:53-59.
76. Li F., Cheng Y., Lu J., Hu R., Wan Q., Feng H. Photodynamic therapy boosts anti-glioma immunity in mice: a dependence on the activities of T cells and complement C3. J. Cell. Biochem. 2011, 112:3035-3043.
77. Cecic I., Korbelik M. Mediators of peripheral blood neutrophilia induced by photodynamic therapy of solid tumors. Cancer Lett. 2002, 183:43-51.
78. Preise D., Oren R., Glinert I., Kalchenko V., Jung S., Scherz A., et al. Systemic antitumor protection by vascular-targeted photodynamic therapy involves cellular and humoral immunity. Cancer Immunol. Immunother. 2009, 58:71-84.
79. Jalili A., Makowski M., Switaj T., Nowis D., Wilczynski G.M., Wilczek E., et al. Effective photoimmunotherapy of murine colon carcinoma induced by the combination of photodynamic therapy and dendritic cells. Clin. Cancer Res. 2004, 10:4498-4508.
80. Gollnick S.O., Owczarczak B., Maier P. Photodynamic therapy and anti-tumor immunity. Lasers Surg. Med. 2006, 38:509-515.
81. Sur B.W., Nguyen P., Sun C.-H., Tromberg B.J., Nelson E.L. Immunophototherapy using PDT combined with rapid intratumoral dendritic cell injection. Photochem. Photobiol. 2008, 84:1257-1264.
82. Gollnick S.O., Vaughan L., Henderson B.W. Generation of effective antitumor vaccines using photodynamic therapy. Cancer Res. 2002, 62:1604-1608.
83. Kushibiki T., Tajiri T., Tomioka Y., Awazu K. Photodynamic therapy induces interleukin secretion from dendritic cells. Clin. Exp. Med. 2010, 3:110-114.
84. Castano A.P., Mroz P., Hamblin M.R. Photodynamic therapy and anti-tumour immunity. Nat. Rev. Cancer 2006, 6:535-545.
85. Canti G., De Simone A., Korbelik M. Photodynamic therapy and the immune system in experimental oncology. Photochem. Photobiol. Sci. 2002, 1:79-80.
86. Korbelik M., Sun J., Cecic I. Photodynamic therapy-induced cell surface expression and release of heat shock proteins: relevance for tumor response. Cancer 2005, 1018-1026.
87. Korbelik M., Stott B., Sun J. Photodynamic therapy-generated vaccines: relevance of tumour cell death expression. Br. J. Cancer 2007, 97:1381-1387.
88. Rubartelli A., Lotze M.T. Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol. 2007, 28:429-436.
89. Garg A.D., Nowis D., Golab J., Agostinis P. Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity. Apoptosis 2010, 15:1050-1071.
90. Garg A.D., Krysko D.V., Vandenabeele P., Agostinis P. DAMPs and PDT-mediated photo-oxidative stress: exploring the unknown. Photochem. Photobiol. Sci. 2011, 10:670-680.
91. Yenari M.A., Liu J., Zheng Z., Vexler Z.S., Lee J.E., Giffard R.G. Antiapoptotic and anti-inflammatory mechanisms of heat-shock protein protection. Ann. N. Y. Acad. Sci. 2005, 1053:74-83.
92. Garg A.D., Krysko D.V., Vandenabeele P., Agostinis P. Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin. Cancer Immunol. Immunother. 2012, 61:215-221.
93. Elmets C.A., Bowen K.D. Immunological Suppression in Mice Treated with Hematoporphyrin Derivative Photoradiation Immunological Suppression in Mice Treated with Hematoporphyrin Derivative. Animals 1986, 1608-1611.
94. Simkin G.O., King D.E., Levy J.G., Chan A.H., Hunt D.W. Inhibition of contact hypersensitivity with different analogs of benzoporphyrin derivative. Immunopharmacology 1997, 37:221-230.
95. Musser D.A., Fiel R.J. Cutaneous photosensitizing and immunosuppressive effects of a series of tumor localizing porphyrins. Photochem. Photobiol. 1991, 53:119-123.
96. Simkin G.O., Tao J.S., Levy J.G., Hunt D.W. IL-10 contributes to the inhibition of contact hypersensitivity in mice treated with photodynamic therapy. J. Immunol. 2000, 164:2457-2462.
97. Gollnick S.O., Musser D.A., Oseroff A.R., Vaughan L., Owczarczak B., Henderson B.W. IL-10 does not play a role in cutaneous Photofrin photodynamic therapy-induced suppression of the contact hypersensitivity response. Photochem. Photobiol. 2001, 74:811-816.
98. Yusuf N., Katiyar S.K., Elmets C.A. The immunosuppressive effects of phthalocyanine photodynamic therapy in mice are mediated by CD4+ and CD8+ T cells and can be adoptively transferred to naive recipients. Photochem. Photobiol. 2008, 84:366-370.
99. Matthews Y.J., Damian D.L. Topical photodynamic therapy is immunosuppressive in humans. Br. J. Dermatol. 2010, 637-641.
100. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Lowe S.W., et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996, 379:88-91.
101. Kondo A., Safaei R., Mishima M., Niedner H., Lin X., Howell S.B. Hypoxia-induced enrichment and mutagenesis of cells that have lost DNA mismatch repair. Cancer Res. 2001, 61:7603-7607.
102. Kim J.-Whan, Tchernyshyov I., Semenza G.L., Dang C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006, 3:177-185.
103. Salceda S., Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J. Biol. Chem. 1997, 272:22642-22647.
104. Schofield C.J., Ratcliffe P.J. Signalling hypoxia by HIF hydroxylases. Biochem. Biophys. Res. Commun. 2005, 338:617-626.
105. Valko M., Rhodes C.J., Moncol J., Izakovic M., Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem. Biol. Interact. 2006, 160:1-40.
106. Ma X.-H., Piao S., Wang D., McAfee Q.W., Nathanson K.L., Lum J.J., et al. Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma. Clin. Cancer Res. 2011, 17:3478-3489.
107. Kang R., Zeh H.J., Lotze M.T., Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ. 2011, 18:571-580.
108. Jin S., White E. Tumor suppression by autophagy through the management of metabolic stress. Autophagy 2008, 4:563-566.
109. Amaravadi R.K., Thompson C.B. The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin. Cancer Res. 2007, 13:7271-7279.
110. Liu X.-W., Su Y., Zhu H., Cao J., Ding W.-J., Zhao Y.-C., et al. HIF-1α-dependent autophagy protects HeLa cells from fenretinide (4-HPR)-induced apoptosis in hypoxia. Pharmacol. Res. 2010, 62:416-425.
111. Sieroń A., Adamek M., Kawczyk-Krupka A., Mazur S., Ilewicz L. Photodynamic therapy (PDT) using topically applied delta-aminolevulinic acid (ALA) for the treatment of oral leukoplakia. J. Oral Pathol. Med. 2003, 32:330-336.
112. Perona R., Sánchez-Pérez I. Control of oncogenesis and cancer therapy resistance. Br. J. Cancer 2004, 90:573-577.
113. Kitano H. Cancer as a robust system: implications for anticancer therapy. Nat. Rev. Cancer 2004, 4:227-235.
114. Scherz-Shouval R., Shvets E., Fass E., Shorer H., Gil L., Elazar Z. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J. 2007, 26:1749-1760.
115. Nyström T. Role of oxidative carbonylation in protein quality control and senescence. EMBO J. 2005, 24:1311-1317.
116. Reiners J.J., Agostinis P., Berg K., Oleinick N.L., Kessel D. Assessing autophagy in the context of photodynamic therapy. Autophagy 2010, 6:7-18.
117. Pattingre S., Tassa A., Qu X., Garuti R., Liang X.H., Mizushima N., et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005, 122:927-939.
118. Kim H.R., Luo Y., Li G., Kessel D. Enhanced apoptotic response to photodynamic therapy after bcl-2 transfection. Cancer Res. 1999, 59:3429-3432.
119. Kessel D., Castelli M. Evidence that bcl-2 is the target of three photosensitizers that induce a rapid apoptotic response. Photochem. Photobiol. 2001, 74:318-322.
120. Dewaele M., Martinet W., Rubio N., Verfaillie T., de Witte P.A., Piette J., et al. Autophagy pathways activated in response to PDT contribute to cell resistance against ROS damage. J. Cell. Mol. Med. 2011, 15:1402-1414.
121. Agostinis P., Berg K., Cengel K.A., Foster T.H., Girotti A.W., Gollnick S.O., et al. Photodynamic therapy of cancer: an update. CA Cancer J. Clin. 2011, 61:250-281.
122. Bellot G., Garcia-Medina R., Gounon P., Chiche J., Roux D., Pouysségur J., et al. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol. Cell. Biol. 2009, 29:2570-2581.
123. Davids L.M., Kleemann B., Cooper S., Kidson S.H. Melanomas display increased cytoprotection to hypericin-mediated cytotoxicity through the induction of autophagy. Cell Biol. Int. 2009, 33:1065-1072.
124. Mathew R., Karantza-Wadsworth V., White E. Assessing metabolic stress and autophagy status in epithelial tumors. Methods Enzymol. 2009, 453:53-81.
125. Karantza-Wadsworth V., Patel S., Kravchuk O., Chen G., Mathew R., Jin S., et al. Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev. 2007, 21:1621-1635.
126. Mathew R., Kongara S., Beaudoin B., Karp C.M., Bray K., Degenhardt K., et al. Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev. 2007, 21:1367-1381.
127. Degenhardt K., Mathew R., Beaudoin B., Bray K., Anderson D., Chen G., et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 2006, 10:51-64.
128. Henderson B.W., Fingar V.H. Oxygen limitation of direct tumor cell kill during photodynamic treatment of a murine tumor model. Photochem. Photobiol. 1989, 49:299-304.
129. Eng C.H., Abraham R.T. The autophagy conundrum in cancer: influence of tumorigenic metabolic reprogramming. Oncogene 2011, 30:4687-4696.